Bio-Thera Solutions Demonstrated High Similarity Between BAT1706, a proposed biosimilar of bevacizumab and Reference Bevacizumab
Shots:
- The study showed that a proposed biosimilar BAT1706 & reference bevacizumab (EU/US-sourced Avastin) demonstrate high similarity in terms of physicochemical & functional attributes
- BAT1706 was shown to have an identical amino acid sequence and an indistinguishable higher-order structure over EU/US-bevacizumab. BAT1706 & also exhibited similar post-translational modifications, glycan profiles, and charge variants
- Potency was assessed using a wide range of bioassays and was also shown to be comparable b/w BAT1706 and EU/US-bevacizumab with statistical equivalence for VEGF-A binding and neutralizing activity. Bevacizumab, a VEGF- targeting biologic used to treat multiple cancers, incl. metastatic colorectal cancer
Ref: Center For Biosimilars | Image: Bio-Thera Solutions
Related News:- Bio-Thera Solutions Reports the US FDA's Acceptance of BLA for BAT1706 (Proposed Biosimilar to Avastin)
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
